Results 221 to 230 of about 164,975 (264)

Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Aging Cell, 2016
Dudley W. Lamming, Sebastian I Arriola Apelo, Michelle E Kimple   +2 more
exaly  

Rapamycin: An anti-cancer immunosuppressant?

Critical Reviews in Oncology/Hematology, 2005
Brian K Law
exaly  

Investigation of rapamycin and rapamycin metabolites

2001
openaire   +1 more source

Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.

Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011
Randy Strong, Joseph A. Baur
exaly  

Atomic Structures of the Human Immunophilin FKBP-12 Complexes with FK506 and Rapamycin

Journal of Molecular Biology, 1993
Robert F. Standaert, Jon Clardy, Gregory D Van Duyne   +2 more
exaly  

Rapamycin encapsulated in dual-responsive micelles for cancer therapy

Biomaterials, 2013
Chun-Liang Lo, Yi-Chun Chen, Ging-Ho Hsiue   +2 more
exaly  

Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways

Oncogene, 2006
Shile Huang, John Blenis
exaly  

Rapamycin derivatives

2019
BONAZZI SIMONE, CONNOLLY MICHAEL, GLASS DAVID JONATHAN, MIHALIC MANUEL, PATTERSON ANDREW WILLIAM, ROGGO SILVIO, SHAVLAKADZE TEA   +6 more
openaire   +3 more sources

Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins

Aging Cell, 2015
Brian K Kennedy, Chen-Yu Liao, Emmeline C Academia   +2 more
exaly  

RAPAMYCIN COMPOSITION

2013
PIETRZYNSKI GRZEGORZ, ALAKHOV VALERY, PATEL KISHORE   +2 more
openaire   +3 more sources